GeneNews Ltd. launched BreastSentry, a blood-based biomarker test to assess risk of breast cancer.

The test, launched via the company's Virginia clinical reference lab Innovative Diagnostics Laboratory, measures the fasting plasma levels of two blood biomarkers which are "highly predictive" of the risk for developing breast cancer, GeneNews said.

The test is intended for use by women who are at average risk and have no family of history of breast cancer. The company said BreastSentry is especially suited for the 50% of U.S. women with dense breast tissue, who cannot rely solely on mammography to detect whether they have breast cancer.